MannKind Launches Educational Website to Raise Awareness of NTM Lung Disease
MannKind Launches Educational Website to Raise Awareness of NTM Lung Disease
Pulmonary NTM infection is a rare disease with a global health impact due to its rising prevalence worldwide and association with shortened life span, high morbidity, and significant impact on patients' quality of life. NTM is a group of bacteria naturally found in our environment, including water and soil, that can lead to cough, fatigue, a reduction in lung function, and poor quality of life among other debilitating symptoms. While most people are exposed to NTM daily, the organisms generally do no harm. Individuals with underlying conditions such as COPD, asthma, and bronchiectasis are at increased risk of NTM getting established in the lungs creating an infection and progressive worsening of lung function.- LearnAboutNTM.com provides information and resources for patients and caregivers
- Site launch in support of World NTM Awareness Day, August 4
- LearnAboutNTm.com为患者和看护人提供信息和资源。
- 支持全球货币世界NTm意识日的网站启动，时间为8月4日。
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today the launch of an educational website designed to raise awareness of nontuberculous mycobacterial (NTM) lung disease. LearnAboutNTM.com is launching today in support of World NTM Awareness Day on August 4.
康州丹伯里和加利福尼亚州西湖村，2024年7月31日 (环球新闻通讯社)-- 曼恩凯德生物医疗公司（Nasdaq: MNKD）今日宣布推出一款教育性网站，以提高人们对非结核分枝杆菌（NTM）肺病的认识 。LearnAboutNTm.com支持8月4日的世界NTM日正式上线。
"NTM lung disease is something many have not heard of before and that often translates to patients going undiagnosed for years," said Dr. Wassim Fares, MSc, FCCP, Senior Vice President, Therapeutic Area Head, Orphan Lung Diseases of MannKind Corporation. "MannKind is dedicated to elevating awareness of NTM, promote early detection and provide a pathway to resources with this website."
“NTm肺病是许多人之前没有听说过的疾病，这通常会导致患者长达多年未被诊断出来，”MannKind Corporation孤儿肺病治疗领域负责人、高级副总裁Wassim Fares博士MSc,FCCP表示，“曼恩凯德致力于提高人们对NTm肺病的认识，促进早期发现，并通过该网站提供资源的途径。”
"It's inspiring that more companies like MannKind are using their voice to amplify awareness of NTM and provide an educational tool for patients living with the disease," said Amy Leitman, JD, president of NTM Info & Research, a nonprofit advocacy group for patients with pulmonary nontuberculous mycobacterial disease. "Raising awareness helps people know the signs and for patients to access resources and ultimately timely diagnoses with physicians for optimum treatment."
"曼恩凯德等更多公司正在积极提高NTm意识并为患有该疾病的患者提供教育工具，这令人鼓舞，" NTm 信息和研究总裁Amy Leitman表示，“提高意识有助于人们了解NTm肺病的迹象，患者能够获取资源，并最终获得及时的诊断和最佳治疗。”
Pulmonary NTM infection is a rare disease with a global health impact due to its rising prevalence worldwide and association with shortened life span, high morbidity, and significant impact on patients' quality of life. NTM is a group of bacteria naturally found in our environment, including water and soil, that can lead to cough, fatigue, a reduction in lung function, and poor quality of life among other debilitating symptoms. While most people are exposed to NTM daily, the organisms generally do no harm. Individuals with underlying conditions such as COPD, asthma, and bronchiectasis are at increased risk of NTM getting established in the lungs creating an infection and progressive worsening of lung function.
由于其在全球范围内患病率的上升和与缩短寿命、高发病率和对患者生活质量的显着影响有关，肺部NTm感染是一种罕见疾病。NTm是一组自然存在于我们的环境中，包括水和土壤中的细菌，它可能导致咳嗽、疲劳、肺功能下降、生活质量降低等其他削弱症状。虽然大多数人每天都会接触NTm，但通常它们对人体没有害处。患有慢性阻塞性肺疾病、哮喘和支气管扩张等基础疾病的个体患病风险增加，使得NTm可以在肺部定居从而导致感染和肺功能逐渐恶化。
There are nearly 200 species of NTM, the most common is MAC (mycobacterium avium complex), which accounts for about 80% of all NTM lung disease cases in the United States. While not everyone is at risk of contracting NTM from MAC, for those who are, it can cause serious lung damage. NTM lung disease is more common in women over the age of 65. Estimated 2022 NTM disease prevalence is more than 100,000 in the U.S. and over 150,000 in Japan. Approximately 15-20% of NTM patients are refractory. The prevalence rate of NTM is increasing globally – within the U.S. alone claims-based studies suggest an annual rise of 7.5%.
共有近200种NTm，其中最常见的是MAC（分枝杆菌性肺病杆菌复合体），在美国所有NTm肺病病例中占大约80%。尽管不是每个人都有感染MAC的NTm的风险，但对于那些有感染风险的人来说，它会导致严重的肺部损伤。NTm肺病在65岁以上的女性中更为常见。据估计，2022年，NTm病的在美国超过10万，日本超过15万。大约15-20%的NTm患者难以治愈。NTm的患病率在全球范围内逐年上升——在美国单独进行的基于索赔的研究表明，每年增长7.5%。
To learn more about NTM, please visit LearnAboutNTM.com.
要了解更多关于NTm，敬请访问LearnAboutNTm.com。
About MannKind
MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of innovative inhaled therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases.
曼恩凯德生物医疗公司（Nasdaq：MNKD）专注于为那些患有内分泌和孤儿肺病的患者开发和商业化创新吸入治疗产品和设备。
我们致力于利用我们的配方能力和设备工程的技术，减轻糖尿病，非结核分枝杆菌（NTM）肺病，肺纤维化和肺动脉高压等疾病的负担。我们的标志性技术——干粉配方和吸入设备——可以快速，方便地向肺的深处输送药物，从而在目标疾病的治疗方面产生局部或进入系统循环的作用，具体取决于治疗目标。
We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, nontuberculous mycobacterial (NTM) lung disease, pulmonary fibrosis, and pulmonary hypertension. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation, depending on the target indication.
我们致力于利用我们的配方能力和设备工程专业知识减轻糖尿病、非结核分枝杆菌（NTM）肺病、肺纤维化和肺动脉高压等疾病的负担。我们的标志性技术——干粉制剂和吸入设备——为药物快速、便捷地输送到深层肺部提供了可能，这些药物可以在当地发挥功效，也可以进入系统循环，具体取决于治疗指示。
With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life.
在曼恩凯德生物医疗的全国性合作团队的热情协作下，我们的使命是让人们掌控自己的健康和自由生活。
Please visit mannkindcorp.com to learn more, and follow us on LinkedIn, Facebook, X or Instagram.
请访问mannkindcorp.com获取更多信息，并在LinkedIn、Facebook、X或Instagram上关注我们。
MANNKIND is a registered trademark of MannKind Corporation.
曼恩凯德生物医疗是曼恩凯德的已注册商标。
MannKind Contacts:
Corporate Communications
Christie Iacangelo
(818) 292-3500
Email: media@mnkd.com
Investor Relations
(818) 661-5000
Email: ir@mnkd.com
曼恩凯德生物医疗联系人：
企业通讯
电子邮件：media@mnkd.com
（818）292-3500
电子邮件：ir@mnkd.com
投资者关系
(818) 661-5000
电子邮件：ir@mnkd.com
Source: MannKind
来源：曼恩凯德生物医疗
